ProCE Banner Activity

PACS: Sintilimab Plus Paclitaxel and Cisplatin as Neoadjuvant Treatment for FIGO Stage IB3 and IIA2 Cervical Cancer

Conference Coverage
Slideset

In the phase II PACS trial, sintilimab plus paclitaxel and cisplatin as neoadjuvant treatment for FIGO stage IB3 and IIA2 cervical cancer resulted in a pathologic complete response rate of 36.2% with an objective response rate of 97.5%.

Released: June 27, 2024

Expiration: June 26, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from GSK.

GSK